Hudson Bay Capital Management
KLRS

Hudson Bay Capital Management’s Kalaris Therapeutics KLRS Stock Holding History

Hudson Bay Capital Management’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-13,284
Closed -$1.04M – 986
2023
Q2 		$1.04M Buy
+13,284
New +$1.26M 0.01% 585

Other funds holding KLRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Hudson Bay Capital Management's KLRS Position: Q3 2023 in Review

Hudson Bay Capital Management sold out of Kalaris Therapeutics (KLRS) in Q3 2023, closing a stake of 13,284 shares — an estimated $1.04M sold.

Hudson Bay Capital Management first reported a position in KLRS in Q2 2023 and held it in 1 quarter. The position peaked at $1.04M in Q2 2023. 90 funds tracked by Wall St. Rank hold KLRS as of Q3 2023.

  • Hudson Bay Capital Management reported no remaining Kalaris Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Hudson Bay Capital Management sold 13,284 Kalaris Therapeutics shares in Q3 2023, an estimated $1.04M.
  • Hudson Bay Capital Management first reported a position in Kalaris Therapeutics in Q2 2023 and held it in 1 quarter.
  • Hudson Bay Capital Management's Kalaris Therapeutics position peaked at $1.04M in Q2 2023.
  • 90 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q3 2023.

Based on Hudson Bay Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.